New diagnostic criteria of leukemic systemic mastocytosis and myelomastocytic leukemia
https://doi.org/10.18821/0234-5730-2016-61-2-110-112
Abstract
Mast cell leukemia is characterized by proliferation and accumulation of immature mast cells in the bone marrow and other organs. The difficulties exist in the differential diagnosis of leukemic systemic mastocytosis and myelomastocytic leukemia. Although in both cases diagnostic criteria are reported, some questions about the terms remain to be open. This problem was discussed by the EU/US-consensus group and the European Competence Network on Mastocytosis (ECNM) in 2011--2013. The diagnosis of myelomastocytic leukemia as myeloid tumor with a large number of mast cells was proposed as eligible in the absence of diagnostic criteria of mastocytosis. It was also recommended to divide leukemic systemic mastocytosis into acute and chronic forms based on the presence or absence of cutaneous manifestations. The primary form of the mast cell leukemia must be differentiated from the secondary, which usually develops in the set of aggressive systemic mastocytosis and mast cell sarcoma. The authors put emphasis on the inevitability of the prephase or leukemic systemic mastocytosis, which is often debut as aggressive systemic mastocytosis with rapid progression and the appearance of from 5 to 19% of mast cells in bone marrow smears. This condition is recommended to call the aggressive systemic mastocytosis in conversion to mast cells leukemia. The expansion of the current WHO classification by incorporating different variants of mast cell leukemia, will optimize the selection of patients for clinical trials.
About the Authors
A. V. Budnevskiy
Voronezh State Medical University n.a. N.N. Burdenko
Russian Federation
Voronezh, 394000
Russian Federation
Voronezh, 394000
E. S. Ovsyannikov
Voronezh State Medical University n.a. N.N. Burdenko
Russian Federation
Russian Federation
Ovsyannikov Evgeny V., MD, PhD, associate professor
Voronezh, 394000
Yu. G. Zhusina
Voronezh State Medical University n.a. N.N. Burdenko
Russian Federation
Voronezh, 394000
Russian Federation
Voronezh, 394000
References
1. Melikyan A.L., Subortseva I.N., Goryacheva S.R., Kolosheynova T.I., Vakhrusheva M.V., Kovrigina A.M., et al. Mastocytosis (literature review and case reports). Therapeutic archive. Russian journal (Terapevticheskiy arkhiv). 2014; 12: 127–34. (in Russian)
2. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., Marone G., et al. Diagnostic criteria and classifcation of mastocytosis: a consensus proposal. Leuk. Res. 2001; 25(7): 603–25.
3. Valent P., Horny H.P., Li C.Y., Longley J.B., Metcalfe D.D., Parwaresch R.M., Bennett J.M. Mastocytosis (mast cell disease). In: Jaffe E.S., Harris N.L., Stein H., Vardiman J.W.; eds. WHO Classifcation of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 291–302.
4. Horny H.P., Akin C., Metcalfe D.D., Escribano L., Bennet J.M., Valent P., Bain B.J. Mastocytosis (mast cell disease). In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al.; eds. WHO Classifcation of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008: 54–63.
5. Valent P., Akin C., Sperr W.R., Horny H.P., Metcalfe D.D. Mast cell proliferative disorders: current view on variants recognized by the WO. Hematol. Oncol. Clin. North. Am. 2003; 17(5): 1227–41.
6. Valent P., Akin C., Sperr W.R., Escribano L., Arock M., Horny H.P., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk. Res. 2003; 27(7): 635–41.
7. Georgin-Lavialle S., Lhermitte L., Dubreuil P., Chandesris M.O., Hermine O., Damaj G. Mast cell leukemia. Blood. 2013; 121(8): 1285–95.
8. Valent P., Samorapoompichit P., Sperr W.R., Horny H.P., Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol. J. 2002; 3(2): 90–4.
9. Arredondo A.R., Gotlib J., Shier L., Medeiros B., Wong K., Cherry A., et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am. J. Hematol. 2010; 85(8): 600–6.
10. Sperr W.R., Drach J., Hauswirth A.W., Ackermann J., Mitterbauer M., Mitterbauer G., et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin. Cancer Res. 2005; 11(19, Pt 1): 6787–92.
11. Wimazal F., Sperr W.R., Horny H.P., Carroll V., Binder B.R., Fonatsch C., et al. Hyperfbrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am. J. Hematol. 1999; 61(1): 66–77.
12. Khaliulin Yu.G. Mastocytosis: clinical manifestations, diagnosis and tactics of treatment of patients. Attending doctor.Russian journal (Lechashchiy vrach). 2012; 8: 83–9. (in Russian)
13. Horny H.P., Parwaresch M.R., Lennert K. Bone marrow fndings in systemic mastocytosis. Hum. Pathol. 1985; 16(8): 808–14.
14. Horny H.P., Sillaber C., Menke D., Kaiserling E., Wehrmann M., Stehberger B., et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 1998; 22(9): 1132–40.
15. Horny H.P., Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemicalfndings. Leuk. Res. 2001; 25(7): 543–51.
16. Sperr W.R., Escribano L., Jordan J.H., Schernthaner G.H., Kundi M., Horny H.P., Valent P. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 2001; 25(7): 529–36.
17. Valent P., Akin C., Escribano L., Födinger M., Hartmann K., Brockow K., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 2007; 37(6): 435–53.
18. Horny H.P., Sotlar K., Stellmacher F., Krokowski M., Agis H., Schwartz L.B., et al. The tryptase positive compact round cell infltrate of the bone marrow (TROCI-BM): a novel histopathological fnding requiring the application of lineage specifc markers. J. Clin. Pathol. 2006; 59(3): 298–302.
19. Krokowski M., Sotlar K., Krauth M.T., Födinger M., Valent P., Horny H.P., et al. Delineation of patterns of bone marrow mast cell infltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am. J. Clin. Pathol. 2005; 124(4): 560–8.
20. Sotlar K., Horny H.P., Simonitsch I., Krokowski M., Aichberger K.J., Mayerhofer M., et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am. J. Surg. Pathol. 2004; 28(10): 1319–25.
21. Valent P., Spanblöchl E., Bankl H.C., Sperr W.R., Marosi C., PircDanoewinata H., et al. Kit ligand/mast cell growth factorindependent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood. 1994; 84(12): 4322–32.
22. Jordan J.H., Walchshofer S., Jurecka W., Mosberger I., Sperr W.R., Wolff K., et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum. Pathol. 2001; 32(5): 545–52.
23. Horny H.P., Greschniok A., Jordan J.H., Menke D.M., Valent P. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study. J. Clin. Pathol. 2003; 56(2): 103–6.
24. Sotlar K., Cerny-Reiterer S., Petat-Dutter K., Hessel H., Berezowska S., Müllauer L., et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod. Pathol. 2011; 24(4): 585–95.
25. Valent P., Sotlar K., Horny H.P. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk. Lymphoma. 2011; 52(5): 740–4.
26. Morgado J.M., Perbellini O., Johnson R.C., Teodosio C., Matito A., Alvarez-Twose I., et al. CD30-expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology. 2013; 63(6): 780–7. doi: 10.1111/his.12221.
27. Valent P., Blatt K., Eisenwort G., Herrmann H., Cerny-Reiterer S., Thalhammer R., et al. FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. Leuk. Res. Rep. 2014; 3(1): 8–13. doi: 10.1016/j.lrr.2013.11.001.
28. van Dongen J.J., Lhermitte L., Bottcher S., Almeida J., van der Velden V.H., Flores-Montero J., et al.; EuroFlow Consortium (EU-FP6, LSHBCT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9): 1908–75. doi: 10.1038/leu.2012.120.
29. Gotlib J., Pardanani A., Akin C., Reiter A., George T., Hermine O., et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013; 121(13): 2393–401. doi: 10.1182/blood-2012-09-458521.
Review
For citations:
Budnevskiy A.V., Ovsyannikov E.S., Zhusina Yu.G. New diagnostic criteria of leukemic systemic mastocytosis and myelomastocytic leukemia. Russian journal of hematology and transfusiology. 2016;61(2):110-112. (In Russ.) https://doi.org/10.18821/0234-5730-2016-61-2-110-112
Views:
1413
Email this article 
